GLEOLAN (aminolevulinic acid hydrochloride) powder for solution – full prescribing information (2026)

Government Record · NX Development Corp; FDA-approved labeling via DailyMed (US NLM) · January 29, 2026

NX Development Corp et al., 2026-01-29: US label for aminolevulinic acid (Gleolan): its approved use in glioma is fluorescence visualisation during surgery, not photodynamic therapy – the approved brain-tumour photosensitizer in the US does not treat, it illuminates.

Gleolan is indicated in patients with glioma [suspected World Health Organization (WHO) Grades III or IV on preoperative imaging] as an adjunct for the visualization of malignant tissue during surgery.

Section 1 (Indications and Usage)

NX Development Corp et al., 2026-01-29: US label for aminolevulinic acid (Gleolan): its approved use in glioma is fluorescence visualisation during surgery, not photodynamic therapy – the approved brain-tumour photosensitizer in the US does not treat, it illuminates. C8 label record – glioblastoma/brain. Country: USA. Dose on the label: 20 mg/kg orally 3 hours before anaesthesia. Not methylene blue. Establishes that the FDA-approved agent in brain tumours is a surgical visualisation adjunct. Study type: regulatory record.